Ключові слова
посттравматичний стресовий розлад
катехоламінергічна дисфункція
празозин
доксазозин
клонідин
пропранолол
ребокситин
атомоксетин
метилфенідат
L-DOPA
кветіапін
арипіпразол
брексипіпразол
катехоламінергічна дисфункція
празозин
доксазозин
клонідин
пропранолол
ребокситин
атомоксетин
метилфенідат
L-DOPA
кветіапін
арипіпразол
брексипіпразол
Анотація
З позицій сучасних знань вважається, що катехоламінергічна дисрегуляція відіграє важливу роль у патофізіології посттравматичного стресового розладу (ПТСР), а маніпуляції з взаємопов’язаними норадренергічною (NEergic) і дофамінергічною (DAergic) системами призводять до зміни поведінкових реакцій на стрес. Це робить зазначені системи привабливими об’єктами фармакотерапії ПТСР і обґрунтовує потенційну корисність специфічно спрямованих на NEergic і DAergicтсистеми лікарських засобів у лікуванні людини, яка пережила психологічну травму. Мета дослідження – збір, аналіз та узагальнення даних із ресурсів Internet (PubMed, MEDLINE, Web of Science, ClinicalTrials.gov, Drugbank) щодо місця та ролі NEergic і DAergic систем у патогенезі ПТСР та останніх трендів у сфері пошуку засобів фармакологічної корекції їхньої дисфункції при цьому патологічному стані. Як перспективні препарати для включення в протоколи лікування ПТСР розглядають агоністцентральних α2AR (клонідин), антагоністи α1AR (празозин, доксазозин), β-адренергічні препарати (пропранолол), інгібітори NET (ребоксетин, атомоксетин), стимулятори DAergic та NEergic систем (метилфенідат), попередник DA – L-DOPA, атипові антипсихотики (кветіапін, арипіпразол, брекспіпразол) з позитивним впливом на різні ланки NEergic і DAergic дисфункції. Розширення спектра препаратів із селективною дією на певні ланки NEergic і DAergic дисфункції та оптимізація схем і методів моно- та комбінованої терапії ПТСР потребує подальших фундаментальних і прикладних доклінічних досліджень і клінічних випробувань.
Посилання
1. Catecholamine responses to virtual combat: implications for post-traumatic stress and dimensions of functioning. K. B. Highland, M. E. Costanzo, T. Jovanovic et al. Front. Psychol. 2015. V. 6. P. 256. https://doi.org/10.3389/fpsyg.2015.00256.
2. Effects of trauma-related audiovisual stimulation on cerebrospinal fluid norepinephrine and corticotropin-releasing hormone concentrations in post-traumatic stress disorder. T. J. Geracioti, D. G. Baker, J. W. Kasckow et al. Psychoneuroendocrinology. 2008. V. 33 (4). P. 416–424. https://doi.org/10.1016/j.psyneuen.2007.12.012. Epub 2008 Mar 4.
3. Putative dopamine agonist (KB220Z) attenuates lucid nightmares in PTSD patients: role of enhanced brain reward functional connectivity and homeostasis redeeming joy. T. McLaughlin, K. Blum, M. Oscar-Berman et al. J. Behav. Addict. 2015. V. 4 (2). P. 106–115. https://doi.org/10.1556/2006.4.2015.008.
4. O'Donnell T., Hegadoren K. M., Coupland N. C. Noradrenergic mechanisms in the pathophysiology of post-traumatic stress disorder. Neuropsychobiology. 2004. V. 50. P. 273–283. https://doi.org/10.1159/000080952.
5. Lee J. H., Lee S., Kim J. Amygdala circuits for fear memory: a key role for dopamine regulation. Neuroscientist. 2017. V. 23 (5). P. 542–553. https://doi.org/10.1177/1073858416679936. Epub 2016 Nov 21.
6. Redundant catecholamine signaling consolidates fear memory via phospholipase C. M. Ouyang, M. B. Young, M. M. Lestini et al. J. Neurosci. 2012. V. 32 (6). P. 1932–1941. https://doi.org/10.1523/JNEUROSCI.5231-11.2012.
7. Dissociation of the role of the prelimbic cortex in interval timing and resource allocation: beneficial effect of norepinephrine and dopamine reuptake inhibitor nomifensine on anxiety-inducing distraction. A. R. Matthews, O. H. He, M. Buhusi, C. V. Buhusi. Front. Integr. Neurosci. 2012. V. 6. P. 111. https://doi.org/10.3389/fnint.2012.00111. eCollection 2012.
8. Regulation of the fear network by mediators of stress: norepinephrine alters the balance between cortical and subcortical afferent excitation of the lateral amygdala. L. R. Johnson, M. Hou, E. M. Prager, J. E. LeDoux. Front. Behav. Neurosci. 2011. V. 5. P. 23. doi: 10.3389/fnbeh.2011.00023. eCollection 2011.
9. Eiden L. E. Neuropeptide-catecholamine interactions in stress. Adv. Pharmacol. 2013. V. 68. P. 399–404. https://doi.org/10.1016/B978-0-12-411512-5.00018-X.
10. Aubry A. V., Serrano P. A., Burghardtl N. S. Molecular mechanisms of stress-induced increases in fear memory consolidation within the amygdala. Front. Behav. Neurosci. 2016. V. 10. P. 191. https://doi.org/10.3389/fnbeh.2016.00191. eCollection 2016.
11. Pezze M., Feldon J. Mesolimbic dopaminergic pathways in fear conditioning. Prog. Neurobiol. 2004. V. 74 (5). P. 301–320. https://doi.org/10.1016/j.pneurobio.2004.09.004.
12. Low platelet-poor plasma concentrations of serotonin in patients with combat-related posttraumatic stress disorder. B. Spivak, Y. Vered, E. Graff et al. Biological Psychiatry. 1999. V. 4 (57). P. 840–845. https://doi.org/10.1016/S0006-3223(98)00231-5.
13. Higher cerebrospinal fluid homovanillic acid levels in depressed patients with comorbid posttraumatic stress disorder. L. Sher, M. A. Oquendo, S. Li et al. Eur. Neuropsychopharmacol. 2005. V. 15 (2). P. 203–209. https://doi.org/10.1016/j.euroneuro.2004.09.009.
14. Hendrickson R. C., Raskind M. A. Noradrenergic dysregulation in the pathophysiology of PTSD. Exp. Neurol. 2016. V. 284 (Pt B). P. 181–195. https://doi.org/10.1016/j.expneurol.2016.05.014. Epub 2016 May 2.1.
15. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride. J. C. Pruessner, F. Champagne, M. J. Meaney, A. Daghe. J. Neurosci. 2004. V. 24 (11). P. 2825–2831. https://doi.org/10.1523/JNEUROSCI.3422-03.2004.
16. Therapeutic challenges of post-traumatic stress disorder: focus on the dopaminergic system. S. A. Torrisi, G. M. Leggio, F. Drago, S. Salomone. Front. Pharmacol. 2019. V. 10. P. 404. https://doi.org/10.3389/fphar.2019.00404. eCollection 2019.
17. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. S. M. Southwick, J. D. Bremner, A. Rasmusson et al. Biological Psychiatry. 1999. V. 46 (9). P. 1192–1204.
18. CSF norepinephrine concentrations in posttraumatic stress disorder. T. D. Geracioti, D. G. Baker, N. N. Ekhator et al. Am. J. Psychiatr. 2001. V. 158. P. 1227–1230. https://doi.org/10.1176/appi.ajp.158.8.1227.
19. Enhanced noradrenergic activity in the amygdala contributes to hyperarousal in an animal model of PTSD. G. Ronzoni, A. Del Arco, F. Mora, G. Segovia. Psychoneuroendocrinology. 2016. V. 70. P. 1–9. https://doi.org/10.1016/j.psyneuen.2016.04.018. Epub 2016 Apr 25.
20. Abnormal noradrenergic function in posttraumatic stress disorder. S. M. Southwick, J. H. Krystal, C. A. Morgan et al. Arch. Gen. Psychiatr. 1993. V. 50. P. 266–274. https://doi.org/10.1001/archpsyc.1993.01820160036003.
21. Nocturnal/daytime urine noradrenergic measures and sleep in combat-related PTSD. T. A. Mellman, A. Kumar, R. Kulick-Bell et al. Biol. Psychiatr. 1995. V. 38. P. 174–179. https://doi.org/10.1016/0006-3223(94)00238-X.
22. Comparing the effect of prazosin and hydroxyzine on sleep quality in patients suffering from posttraumatic stress disorder. M. Ahmadpanah, P. Sabzeiee, S. M. Hosseini et al.
Neuropsychobiology. 2014. V. 69. P. 235–242. https://doi.org/10.1159/000362243.
23. Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US military veterans. A. Germain, R. Richardson, D. E. Moul et al. J. Psychosom. Res. 2012. V. 72. P. 89–96. https://doi.org/10.1016/j.jpsychores.2011.11.010.
24. Pitman R. K. Post-traumatic stress disorder, hormones, and memory. Biol. Psychiatry. 1989. V. 26 (3). P. 221–223.
25. Beta-adrenergic activation and memory for emotional events. L. Cahill, B. Prins, M. Weber, J. L. McGaugh. Nature. 1994. V. 371 (6499). P. 702–704. https://doi.org/10.1038/371702a0.
26. Stress reactivity links childhood trauma exposure to an admixture of depressive, anxiety, and psychosis symptoms. M. van Nierop, A. Lecei, I. Myin-Germeys et al. Psychiatr. Res. 2018. V. 260. P. 451–457. https://doi.org/10.1016/j.psychres.2017.12.012.
27. Sympathetic activity and hypothalamo-pituitary–adrenal axis activity during sleep in post- traumatic stress disorder: a study assessing polysomnography with simultaneous blood sampling. S. van Liempt, J. Arends, P. J. M. Cluitmans et al. Psychoneuroendocrinology. 2013. V. 38. P. 155–165. https://doi.org/10.1016/j.psyneuen.2012.05.015.
28. Post-traumatic stress influences the brain even in the absence of symptoms: a systematic, quantitative meta-analysis of neuroimaging studies. Stark E. A., Parsons C. E., T. J. van Hartevelt et al. Neurosci. Biobehav. Rev. 2015. V. 56. P. 207–221. https://doi.org/10.1016/j.neubiorev.2015.07.007.
29. Evidence for altered brain reactivity to norepinephrine in veterans with a history of traumatic stress. R. C. Hendrickson, M. A. Raskind, S. P. Millard et al. Neurobiol. Stress. 2018. V. 8. P. 103–111. https://doi.org/10.1016/j.ynstr.2018.03.001.
30. Amara S. G., Kuhar M. J. Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 1993. V. 16. P. 73–93. https://doi.org/10.1146/annurev.ne.16.030193.000445.
31. Pharmacology and distribution of norepinephrine transporters in the human locus coeruleus and raphe nuclei. G. A. Ordway, C. A. Stockmeier, G. W. Cason, V. Klimek. J. Neurosci. 1997. V. 17 (5). P. 1710–1719. https://doi.org/10.1523/JNEUROSCI.17-05-01710.1997.
32. Substrate binding stoichiometry and kinetics of the norepinephrine transporter. J. W. Schwartz, G. Novarino, D. W. Piston, L. J. DeFelice. J. Biol. Chem. 2005. V. 280 (19). P. 19177–19184. https://doi.org/10.1074/jbc.M412923200. Epub 2005 Mar 9.
33. Torres G. E., Gainetdinov R. R., Caron M. G. Plasma membrane monoamine transporters: structure, regulation and function. Nat. Rev. Neurosci. 2003. V. 4 (1). P. 13–25. https://doi.org/10.1038/nrn1008.
34. Hansen N. The longevity of hippocampus-dependent memory is orchestrated by the locus coeruleus-noradrenergic system. Neural. Plast. 2017. V. 2017. P. 2727602. https://doi.
org/10.1155/2017/2727602. Epub 2017 Jun 11.
35. Role of brain norepinephrine in the behavioral response to stress. D. A. Morilak, G. Barrera, D. J. Echevarria et al. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2005. V. 29 (8). P. 1214–1224. https://doi.org/10.1016/j.pnpbp.2005.08.007. Epub 2005 Oct 13.
36. Sara S. J., Bouret S. Orienting and reorienting: the locus coeruleus mediates cognition through arousal. Neuron. 2012. V. 76 (1). P. 130–1341. https://doi.org/10.1016/j.neuron.2012.09.011.
37. Jett J. D., Morilak D. A. Too much of a good thing: blocking noradrenergic facilitation in medial prefrontal cortex prevents the detrimental effects of chronic stress on cognition.
Neuropsychopharmacology. 2013. V. 38 (4). P. 585–595. https://doi.org/10.1038/npp.2012.216. Epub 2012 Nov 7.
38. Chronic stress increases the plasmalemmal distribution of the norepinephrine transporter and the coexpression of tyrosine hydroxylase in norepinephrine axons in the prefrontal cortex. L. H. Miner, H. P. Jedema, F. W. Moore et al. J. Neurosci. 2006. V. 26 (5. P. 1571–1578. https://doi.org/10.1523/JNEUROSCI.4450-05.2006.
39. Howells F. M., Stein D. J., Russell V. A. Synergistic tonic and phasic activity of the locus coeruleus norepinephrine (LC-NE) arousal system is required for optimal attentional
performance. Metab. Brain Dis. 2012. V. 27 (3). P. 267–274. https://doi.org/10.1007/s11011-012-9287-9. Epub 2012 Mar 8.
40. Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus. R. H. Pietrzak, J-D. Gallezot, Yu-Sh. Ding et al. JAMA Psychiatry. 2013. V. 70 (11). P. 1199–1205. doi:10.1001/jamapsychiatry.2013.399.
41. Norepinephrine transporter (NET) promoter and 5′-UTR polymorphisms: association analysis in panic disorder. Y. J. Lee, C. Hohoff, K. Domschke et al. Neurosci. Lett. 2005. V. 377 (1). P. 40–43. doi: 10.1016/j.neulet.2004.11.063. Epub 2004 Dec 15.
42. Association of the rs2242446 polymorphism in the norepinephrine transporter gene SLC6A2 and anxious arousal symptoms of posttraumatic stress disorder. R. H. Pietrzak, J. A. Sumner, A. E. Aiello et al. J. Clin. Psychiatry. 2015. V. 76 (4). P. e537-8. doi: 10.4088/JCP.14l09346.
43. Variable response of norepinephrine transporter to traumatic stress and relationship to hyperarousal. Ch. Nwokafor, L. I. Serovarax, A. Tanelian et al. Front. Behav. Neurosci. 2021. V. 15. P. 725091. https://doi.org/10.3389/fnbeh.2021.725091. eCollection 2021.
44. Chronic social defeat up-regulates expression of norepinephrine transporter in rat brains. P. Chen, Y. Fan, Y. Li et al. Neurochem. Int. 2012. V. 60 (1). P. 9–20. https://doi.org/10.1016/j.neuint.2011.11.003.Epub 2011 Nov 15.
45. Corticosterone administration up-regulated expression of norepinephrine transporter and dopamine β-hydroxylase in rat locus coeruleus and its terminal regions. Y. Fan, P. Chen, Y. Liet al. J. Neurochem. 2014. V. 128 (3). P. 445–458. https://doi.org/10.1111/jnc.12459. Epub 2013 Oct 10.
46. An epigenome-wide association study of posttraumatic stress disorder in US veterans implicates several new DNA methylation loci. M. W. Logue, M. W. Miller, E. J. Wolf et al. Clin. Epigenetics. 2020. V. 12 (1). P. 46. https://doi.org/10.1186/s13148-020-0820-0.
47. Association of norepinephrine transporter methylation with in vivo NET expression and hyperactivity-impulsivity symptoms in ADHD measured with PET. H. L. Sigurdardottir, G. S. Kranz, C. Rami-Mark et al. Mol. Psychiatry. 2021. V. 26 (3). P. 1009–1018. https://doi.org/10.1038/s41380-019-0461-x. Epub 2019 Aug 5.
48. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. F. Xu, R. R. Gainetdinov, W. C. Wetsel et al. Nat. Neurosci. 2000. V. 3 (5). P. 465–471. https://doi.org/10.1038/74839.
49. Spoormaker V., Montgomery P. Disturbed sleep in post-traumatic stress disorder: secondary symptom or core feature? Sleep Med. 2008. V. 12 (3). P. 169–184. https://doi.org/10.1016/j.smrv.2007.08.008.
50. Short A., Allan N. P., Schmidt N. B. Sleep disturbance as a predictor of affective functioning and symptom severity among individuals with PTSD: an ecological momentary assessment study. Behav. Res. Ther. 2017. V. 97. P. 146–153. https://doi.org/10.1016/j.brat.2017.07.014. Epub 2017 Jul 27.
51. National institute for health and care excellence. Post-traumatic stress disorder (NICE Quality Standard NG116) 2018 [Internet] c [cited 2019 Sep 9]. URL: https://www.nice.org.uk.guidance/ng116/evidenc.
52. Australian guidelines for the prevention and treatment of acute stress disorder, posttraumatic stress disorder, and complex posttraumatic stress disorder. Phoenix Australia centre for posttraumatic mental health. National health and medical research council. Canberra, Australia, 2020.
53. Veterans health administration, department of defense. VA/DoD clinical practice guideline for the management of post-traumatic stress. Washington : veterans health administration, Department of Defense, 2017.
54. Clinical practice guideline for the treatment of posttraumatic stress disorder (PTSD) in adults. American psychological association, Guideline development panel for the treatment of PTSD in adults. 2017. URL: https://www.apa.org/ptsd-guideline.
55. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo controlled study. M. A. Raskind, E. R. Peskind, E. D. Kanter et al. Am. J. Psychiatry. 2003. V. 160 (2). V. 371–373. https://doi.org/10.1176/appi.ajp.160.2.371.
56. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. M. A. Raskind, E. R. Peskind, D. J. Hoff et al. Biol. Psychiatry. 2007. V. 61 (8). P. 928–934. https://doi.org/10.1016/j.biopsych.2006.06.032.
57. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. M. A. Raskind, K. Peterson, T. Williams et al. Am. J. Psychiatry. 2013. V. 170 (9). P. 1003–1010. https://doi.org/10.1176/appi.ajp.2013.12081133.
58. Naltrexone and prazosin combination for posttraumatic stress disorder and alcohol use disorder. H. Qazi, H. Wijegunaratne, R. Savajiyani, M. M. Koola. Prim. Care Companion CNS Disord. 2014. V. 16 (4). P. 14l01638. https://doi.org/10.4088/PCC.14l01638.
59. Fludrocortisone in posttraumatic stress disorder: effective for symptoms and prazosin-induced hypotension. M. Vaishnav, V. Patel, S. P. Varghese et al. Prim. Care Companion CNS Disord. 2014. V. 16 (6). P. 14l01676. https://doi.org/10.4088/PCC.14l01676.
60. Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety. M. G. Byers, K. M. Allison, C. S. Wendel, J. K. Lee. J. Clin. Psychopharmacol. 2010. V. 30 (3). P. 225–229. https://doi.org/10.1097/JCP.0b013e3181dac52f.
61. Trial of prazosin for post-traumatic stress disorder in military veterans. M. A. Raskind, E. R. Peskind, B. Chow et al. New England Journal of Medicine. 2018. V. 378 (6). P. 507–517.
62. The effects of prazosin on sleep disturbances in post-traumatic stress disorder: a systematic review and meta-analysis. Y. Zhang, R. Ren, L. D. Sanford et al. Sleep Med. 2020. V. 67. P. 225–231. https://doi.org/10.1016/j.sleep.2019.06.010. Epub 2019 Jun 22.
63. Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis. C. Reist, E. Streja, C. C. Tang et al. CNS Spectrums. 2021. V. 26 (4). P. 338–344.
64. Efficacy of prazosin in posttraumatic stress disorder: a systematic review and meta-analysis. B. Singh, A. J. Hughes, G. Mehta et al. Prim. Care Companion CNS Disord. 2016. V. 18 (6).
65. Sethi R., Vasudeva S. Doxazosin for treatment of nightmares: does it really work? A case report. Prim. Care Companion CNS Disord. 2012. V. 14 (5). P. 12l01356. https://doi.org/10.4088/PCC.12l01356.
66. Doxazosin treatment for posttraumatic stress disorder. J. De Jong, P. Wauben, I. Huijbrects et al. J. Clin. Psychopharmacol. 2010. V. 30 (1). P. 84–85. https://doi.org/10.1097/JCP.0b013e3181c827ae.
67. Smith Ch., Koola M. M. Evidence for using doxazosin in the treatment of posttraumatic stress disorder. Psychiatr. Ann. 2016. V. 46 (9). P. 553–555. https://doi.org/10.3928/00485713-20160728-01.
68. Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial. C. Rodgman, C. D. Verrico, M. Holst et al. J. Clin. Psychiatry. 2016. V. 77 (5). P. e561–e565. https://doi.org/10.4088/JCP.14m09681.
69. Doxazosin, an alpha-1-adrenergic-receptor antagonist, for nightmares in patients with posttraumatic stress disorder and/or borderline personality disorder: a chart review. S. Roepke, H. Danker-Hopfe, D. Repantis et al. Pharmacopsychiatry. 2017. V. 50 (1). P. 26–31. https://doi.org/10.1055/s-0042-107794. Epub 2016 Jun 8.
70. Khan D., Richardson C., Forsberg Martin. Doxazosin immediate release as a novel treatment for nightmares in posttraumatic stress disorder. Case Rep. Psychiatry. 2024. V. 2024. P. 6452923. https://doi.org/10.1155/crps/6452923. eCollection 2024.
71. An open-label study of doxazosin extended-release for PTSD: findings and recommendations for future research on doxazosin. A. Richards S., Inslicht, L. M. Ruoff еt al. Focus (Am. Psychiatr. Publ.). 2018. V. 16 (1). P. 67–73. https://doi.org/10.1176/appi.focus.20170031. Epub 2018 Jan 24.
72. Khan Z. P., Ferguson C. N., Jones R. M. Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia. 1999. V. 54 (2). P. 146–165. https://doi.
org/10.1046/j.1365-2044.1999.00659.x.
73. Marchi M., Grenzi P., Boks M. Clonidine for post-traumatic stress disorder: a systematic review of the current evidence. Eur. J. Psychotraumatol. 2024. V. 15 (1). P. 2366049. https://doi.org/10.1080/20008066.2024.2366049. Epub 2024 Jun 28.
74. Inhibition of noradrenaline release by clonidine in the ventral bed nucleus of the stria terminalis attenuates pain-induced aversion in rats. S. Deyama, S. Ide, N. Kondoh et al. Neuropharmacology. 2011. V. 61 (1–2). P. 156–160.
75. Lebow M. A., Chen A. Overshadowed by the amygdala: the bed nucleus of the stria terminalis emerges as key to psychiatric disorders. Molecular Psychiatry. 2016. V. 21 (4). P. 450–463. https://doi.org/10.1038/mp.2016.1.
76. Katic F., Lavery H., Lowe R. D. The central action of clonidine and its antagonism. British Journal of Pharmacology. 1972. V. 44 (4). P. 779–787.
77. Clonidine effects on all-night human sleep: opposite action of low- and medium-dose clonidine on human NREM-REM sleep proportion. S. Miyazaki, S. Uchida, J. Mukai, K. Nishihara. Psychiatry and Clinical Neurosciences. V. 58 (2). P. 138–144.
78. Taking advantage of fear generalization-associated destabilization to attenuate the underlying memory via reconsolidation intervention. F. N. Marin, J. M. Franzen, F. Troyner et al. Neuropharmacology. 2020. V. 181. P. 108338. https://doi.org/10.1016/j.neuropharm.2020.108338. Epub 2020 Sep 28.
79. Activation of a novel α2AAR-spinophilin-cofilin axis determines the effect of α2 adrenergic drugs on fear memory reconsolidation. S. Saggu, Y. Chen, C. Cottingham et al. Molecular Psychiatry. 2023. V. 28 (2). P. 588–600. https://doi.org/10.1038/s41380-022-01851-w.
80. Schulz B., Fendt M., Schnitzler H-U. Clonidine injections into the lateral nucleus of the amygdala block acquisition and expression of fear-potentiated startle. European Journal of Neuroscience. 2002. V. 15 (1). P. 151–157.
81. Low-dose clonidine in veterans with posttraumatic stress disorder. G. A. Burek, M. R. Waite, K. Heslin et al. J. Psychiatr. Res. 2021. V. 137. P. 480–485. https://doi.org/10.1016/j.
jpsychires.2021.03.008. Epub 2021 Mar 16.
82. Treatment of post-traumatic stress disorder nightmares at a veterans affairs medical center. M. B. Detweiler, B. Pagadala, J. Candelario et al. J. Clin. Med. 2016. V. 5 (12). P. 117. https://doi.org/10.3390/jcm5120117.
83. Wendell K. R., Maxwell M. L. Evaluation of clonidine and prazosin for the treatment of nighttime posttraumatic stress disorder symptoms. Fed. Pract. 2015. V. 32 (11). P. 8–14.
84. Eye movement desensitization and reprocessing for mental health problems: a systematic review and meta-analysis. P. Cuijpers, S. C. van Veen, M. Sijbrandij et al. Cogn. Behav. Ther. 2020. V. 49 (3). P. 165–180. https://doi.org/10.1080/16506073.2019.1703801. Epub 2020 Feb 11.
85. Contribution of norepinephrine to emotional memory consolidation during sleep. S. Groch, I. Wilhelm, S. Diekelmann et al. Psychoneuroendocrinology. 2011. V. 36 (9). P. 1342–1350. https://doi.org/10.1016/j.psyneuen.2011.03.006. Epub 2011 Apr 13.
86. Srinivasan A. V. Propranolol: a 50-year historical perspective. Ann. Indian Acad. Neurol. 2019. V. 22 (1). P. 21–26. https://doi.org/10.4103/aian.AIAN_201_18.
87. Giustino T. F., Fitzgerald P. J., Maren S. Revisiting propranolol and PTSD: memory erasure or extinction enhancement? Neurobiol. Learn Mem. 2016. V. 130. P. 26–33. https://doi.org/10.1016/j.nlm.2016.01.009. Epub 2016 Jan 22.
88. Young C., Butcher R. Propranolol for post-traumatic stress disorder: a review of clinical effectiveness. CADTH rapid response report: summary with critical appraisal. Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2020. https://www.ncbi.nlm.nih.gov/books/NBK562942/#rc1254.rl.r1.
89. Propranolol’s impact on cognitive performance in post-traumatic stress disorder. M. Mahabir, A. R. Ashbaugh, D. Saumier, J. Tremblay. J. Affect. Disord. 2016. V. 192. P. 98–103. https://doi.org/10.1016/j.jad.2015.11.051. Epub 2015 Dec 8.
90. Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury. D. C. Orrey, O. I. Halawa, A. V. Bortsov et al. Clin. J. Pain. 2015. V. (1). P. 21–29. https://doi.org/10.1097/AJP.0000000000000086.
91. Altered forebrain neurotransmitter responses to immobilization stress following 3,4-methylenedioxymethamphetamine. L. Matuszewich, M. E. Filon, D. A. Finn, B. K. Yamamoto. Neuroscience. 2002. V. 110 (1). P. 41–48. https://doi.org/10.1016/s0306-4522(01)00539-5.
92. Anxiolytic-like actions of reboxetine, venlafaxine and endurance swimming in stressed male rats. S. Lapmanee, N. Charoenphandhu, N. Krishnamra, J. Charoenphandhu. Behav. Brain Res. 2012. V. 231 (1). P. 20–28. https://doi.org/10.1016/j.bbr.2012.02.037. Epub 2012 Mar 1.
93. Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine. Z. Zhao, A. M. Baros, H-T. Zhang et al. Neuropsychopharmacology. 2008. V. 33 (13). P. 3190–3200. https://doi.org/10.1038/npp.2008.45.
94. Ipser J. C., Stein D. J. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int. J. Neuropsychopharmacol. 2012. V. 15 (6). P. 825–840. https://doi.org/10.1017/S1461145711001209. Epub 2011 Jul 29.
95. Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. I. L. Petrakis, E. Ralevski, N. Desai et al.
Neuropsychopharmacology. 2012. V. 37 (4). P. 996–1004. https://doi.org/10.1038/npp.2011.283.Epub 2011 Nov 16.
96. Therapeutic challenges of post-traumatic stress disorder: focus on the dopaminergic system. S. A. Torrisi, G. M. Leggio, F. Drago, S. Salomone. Front. Pharmacol. 2019. V. 10. P. 404. https://doi.org/10.3389/fphar.2019.00404. eCollection 2019.
97. Lee J. C., Wang L. P., Tsien J. Z. Dopamine rebound-excitation theory: putting brakes on PTSD. Front. Psychiatry. 2016. V. 7. P. 163. https://doi.org/10.3389/fpsyt.2016.00163. eCollection 2016.
98. Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti-reward systems. M. S. Gold, K. Blum, M. Febo et al. Front. Biosci. (Schol Ed). 2018. V. 10 (2). P. 309–325. https://doi.org/10.2741/s518.
99. The medial prefrontal cortex determines the accumbens dopamine response to stress through the opposing influences of norepinephrine and dopamine. T. Pascucci, R. Ventura, E. C. Latagliata et al. Cereb. Cortex. 2007. V. 17 (12). P. 2796–2804. https://doi.org/10.1093/cercor/bhm008. Epub 2007 Feb 24.
100. Cabib S., Puglisi-Allegra S. The mesoaccumbens dopamine in coping with stress. Neurosci Biobehav Rev. 2012. V. 36 (1). P. 79–89. https://doi.org/10.1016/j.neubiorev.2011.04.012. Epub 2011 May 4.
101. Enhancing depression mechanisms in midbrain dopamine neurons achieves homeostatic resilience. A. K. Friedman, J. J. Walsh, B. Juarezet al. Science. 2014. V. 344 (6181). P. 313–319. https://doi.org/10.1126/science.1249240.
102. Torres G. E., Gainetdinov R. R., Caron M. G. Plasma membrane monoamine transporters: structure, regulation and function. Nature Reviews Neuroscience. 2003. V. 4 (1). P. 13–25. https://doi.org/10.1038/nrn1008.
103. Ramamoorthy S., Shippenberg T., Lankupalle J. Regulation of monoamine transporters: role of transporter phosphorylation. Pharmacol. Ther. 2011. V. 129 (2). P. 220–238. https://doi.org/10.1016/j.pharmthera.2010.09.009. Epub 2010 Oct 15.
104. Hillarp N. A., Fuxe K., Dahlstrom A. Demonstration and mapping of central neurons containing dopamine, noradrenaline, and 5-hydroxytryptamine and their reactions to psychopharmaca. Pharmacol. Rev. 1966. V. 18 (1). P. 727–741.
105. Dorsal raphe dopamine neurons represent the experience of social isolation. G. A. Matthews, E. H. Nieh, C. M. Vander Weele et al. Cell. 2016. V. 164 (4). P. 617–631. https://doi.org/10.1016/j.cell.2015.12.040.
106. Dorsal raphe dopamine neurons modulate arousal and promote wakefulness by salient stimuli. J. R. Cho, J. B. Treweek, J. E. Robinson et al. Neuron. 2017. V. 94 (6). P. 1205–1219.e8. https://doi.org/10.1016/j.neuron.2017.05.020. Epub 2017 Jun 8.
107. Dorsal tegmental dopamine neurons gate associative learning of fear. F. Groessl, T. Munsch, S. Meis et al. Nat. Neurosci. 2018. V. 21 (7). P. 952–962. https://doi.org/10.1038/s41593-018-0174-5. Epub 2018 Jun 27.
108. Brewin C. R. Re-experiencing traumatic events in PTSD: new avenues in research on intrusive
memories and flashbacks. Eur. J. Psychotraumatol. 2015. V. 6. P. 27180. https://doi.org/10.3402/ejpt.v6.27180. eCollection 2015.
109. Emotion modulation in PTSD: clinical and neurobiological evidence for a dissociative subtype.
R. A. Lanius, E. Vermetten, R. J. Loewenstein et al. Am. J. Psychiatry. 2010. V. 167 (6). P. 640–647. https://doi.org/10.1176/appi.ajp.2009.09081168. Epub 2010 Apr 1.
110. Hikind N., Maroun M. Microinfusion of the D1 receptor antagonist, SCH23390 into the IL but not the BLA impairs consolidation of extinction of auditory fear conditioning. Neurobiol. Learn Mem. 2008. V. 90 (1). P. 217–222. https://doi.org/10.1016/j.nlm.2008.03.003. Epub 2008 Apr 28.
111. Mueller D., Bravo-Rivera C., Quirk G. J. Infralimbic D2 receptors are necessary for fear extinction and extinction-related tone responses. Biol. Psychiatry. 2010. V. 68 (11). P. 1055–1060. https://doi.org/10.1016/j.biopsych.2010.08.014.
112. Single dose of L-dopa makes extinction memories context-independent and prevents the return of fear. J. Haaker, S. Gaburro, A. Sah et al. Proc. Natl. Acad. Sci. USA. 2013. V. 110 (26). P. E2428–E2436. https://doi.org/10.1073/pnas.1303061110. Epub 2013 Jun 10.
113. Gerlicher A. M. V., Tuscher O., Kalisch R. Dopamine-dependent prefrontal reactivations explain long-term benefit of fear extinction. Nat. Commun. 2018. V. 9 (1). P. 4294. https://doi.org/10.1038/s41467-018-06785-y.
114. Stein M. B., Paulus M. P. Imbalance of approach and avoidance: the yin and yang of anxiety disorders. Biol. Psychiatry. 2009. V. 66 (12). P. 1072–1074. https://doi.org/10.1016/j.
biopsych.2009.09.023.
115. Contreras-Vidal J. L., Schultz W. A predictive reinforcement model of dopamine neurons for learning approach behavior. J. Comput. Neurosci. 1999. V. 6 (3). V. 191–214. https://doi.org/10.1023/a:1008862904946.
116. Schultz W. Behavioral dopamine signals. Trends Neurosci. 2007. V. 30 (5). P. 203–210. https://doi. org/10.1016/j.tins.2007.03.007. Epub 2007 Apr 2.
117. Dopamine enhances signal-to-noise ratio in cortical-brainstem encoding of aversive stimuli. C. M. Vander Weele, C. A. Siciliano, G. A. Matthews et al. Nature. 2018. V. 563 (7731). P. 397–401. https://doi.org/10.1038/s41586-018-0682-1. Epub 2018 Nov 7.
118. Dopamine neurons projecting to the posterior striatum reinforce avoidance of threatening stimuli. W. Menegas, K. Akiti, R. Amo et al. Nat. Neurosci. 2018. V. 21 (10). P. 1421–1430. https://doi.org/10.1038/s41593-018-0222-1. Epub 2018 Sep 3.
119. Striatopallidal neurons control avoidance behavior in exploratory tasks. K. H. LeBlanc, T. D. London, I. Szczot et al. Mol. Psychiatry. 2020. V. 25 (2). P. 491–505. https://doi.org/10.1038/s41380-018-0051-3. Epub 2018 Apr 25.
120. How the brain translates money into force: a neuroimaging study of subliminal motivation. M. Pessiglione, L. Schmidt, B. Draganski et al. Science. 2007. V. 316 (5826). P. 904–906. https://doi.org/10.1126/science.1140459. Epub 2007 Apr 12.
121. Hayes J. P., Vanelzakker M. B., Shin L. M. Emotion and cognition interactions in PTSD: a review of neurocognitive and neuroimaging studies. Front. Integr. Neurosci. 2012. V. 6. P. 89. https://doi.org/10.3389/fnint.2012.00089. eCollection 2012.
122. Anhedonia, reduced cocaine reward, and dopamine dysfunction in a rat model of posttraumatic stress disorder. N. M. Enman, K. Arthur, S. J. Ward et al. Biol. Psychiatry. 2015. V. 78 (12). P. 871–879. https://doi.org/10.1016/j.biopsych.2015.04.024. Epub 2015 May 6.
123. Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse. J. D. Bremner, S. M. Southwick, A. Darnell, D. S. Charney. Am. J. Psychiatry. 1996. V. 153 (3). P. 369–375. https://doi.org/10.1176/ajp.153.3.369.
124. Schell T. L., Marshall G. N., Jaycox L. H. All symptoms are not created equal: the prominent role of hyperarousal in the natural course of posttraumatic psychological distress. J. Abnorm. Psychol. 2004. V. 113 (2). P.189–197. https://doi.org/10.1037/0021-843X.113.2.189.
125. Weston C. S. Posttraumatic stress disorder: a theoretical model of the hyperarousal subtype. Front. Psychiatry. 2014. V. 5. P. 37. https://doi.org/10.3389/fpsyt.2014.00037. eCollection 2014.
126. Dalley J. W., Roiser J. P. Dopamine, serotonin and impulsivity. Neuroscience. 2012. V. 215. P. 42–58. https://doi.org/10.1016/j.neuroscience.2012.03.065. Epub 2012 Apr 25.
127. Cocaine modulation of frontostriatal expression of Zif268, D2, and 5-HT2c receptors in high and low impulsive rats. M. Besson, Y. Pelloux, R. Dilleen et al. Neuropsychopharmacology. 2013. V. 38 (10). P. 1963–1973. https://doi.org/10.1038/npp.2013.95. Epub 2013 May 1.
128. Brain circuit dysfunction in post-traumatic stress disorder: from mouse to man. R. J. Fenster, L. A. M. Lebois, K. J. Ressler, J. Suh. Nat. Rev. Neurosci. 2018. P. 19 (9). P. 535–551. https://doi.org/10.1038/s41583-018-0039-7.
129. Monti J. M., Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med. Rev. 2007. V. 11 (2). P. 113–133. https://doi.org/10.1016/j.smrv.2006.08.003. Epub 2007 Feb 1.
130. Prominent burst firing of dopaminergic neurons in the ventral tegmental area during paradoxical sleep. L. Dahan, B. Astier, N. Vautrelle et al. Neuropsychopharmacology. 2007. V. 32 (6). P. 1232– 1241. https://doi.org/10.1038/sj.npp.1301251.
131. Optogenetic activation of dopamine neurons in the ventral tegmental area induces reanimation from general anesthesia. N. E. Taylor, C. J. Van Dort, J. D. Kenny et al. Proc. Natl. Acad. Sci. USA. 2016. V. 113 (45). P. 12826–12831. https://doi.org/10.1073/pnas.1614340113. Epub 2016 Oct 24.
132. VTA dopaminergic neurons regulate ethologically relevant sleep-wake behaviors. A. Eban- Rothschild, G. Rothschild, W. J. Giardino et al. Nat. Neurosci. 2016. V. 19 (10). P.1356–1366. https://doi.org/10.1038/nn.4377. Epub 2016 Sep 5.
133. Current drug treatments targeting dopamine D3 receptor. G. M. Leggio, C. Bucolo, C. B. Platania et al. Pharmacol. Ther. 2016. V. 165. P. 164–177. https://doi.org/10.1016/j.pharmthera.2016.06.007.Epub 2016 Jun 22.
134. The D2 dopamine receptor (DRD2) gene is associated with co-morbid depression, anxiety and social dysfunction in untreated veterans with post-traumatic stress disorder. B. R. Lawford, R. Young, E. P. Noble et al. European Psychiatry. 2006. V. 21 (3). P. 180–185. https://doi.org/
135. Loiseau F., Millan M. J. Blockade of dopamine D3 receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D1 receptor agonists, but not of D2 antagonists. Eur. Neuropsychopharmacol. 2009. V. 19 (1). P. 23–33. https://doi.org/10.1016/j.
euroneuro.2008.07.012. Epub 2008 Sep 14.
136. The dopamine D3 receptor gene and posttraumatic stress disorder. E. J. Wolf, K. S. Mitchell, M. W. Logue et al. J. Trauma Stress. 2014. V. 27 (4). P. 379–87. https://doi.org/10.1002/jts.21937.
137. Role of dopamine D3 receptor in alleviating behavioural deficits in animal models of post-traumatic stress disorder. D. Song , Y. Ge, Z. Chen et al. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2018. V. 84 (Pt A). P. 190–200. https://doi.org/10.1016/j.pnpbp.2018.03.001. Epub 2018 Mar 3.
138. Dopamine D3 receptor in the nucleus accumbens alleviates neuroinflammation in a mouse modelof depressive-like behavior. J. Wang, S. Lai, R. Wang et al. Brain Behav. Immun. V. 101. P. 165–179. https://doi.org/10.1016/j.bbi.2021.12.019. Epub 2021 Dec 28.
139. COMT as a drug target for cognitive functions and dysfunctions. D. Scheggia, S. Sannino, M. L. Scattoni, F. Papaleo. CNS Neurol. Disord. Drug Targets. 2012. V. 11 (3). P. 209–221. https://doi.org/10.2174/187152712800672481.
140. Diaz-Asper C. M., Weinberger D. R., Goldberg T. E. Catechol-O-methyltransferase polymorphisms and some implications for cognitive therapeutics. NeuroRx. 2006. V. 3 (1). P. 97–105. https://doi.org/10.1016/j.nurx.2005.12.010.
141. Schacht J. P. COMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review. The Pharmacogenomics Journal. 2016. 16 (5). P. 430–438. https://doi.org/10.1038/tpj.2016.43.
142. COMT Val158Met polymorphism is associated with post-traumatic stress disorder and functional outcome following mild traumatic brain injury. E. A. Winkler, J. Yue, A. R. Ferguson et al. J. Clin. Neurosci. 2016. V. 35. P. 109–116. https://doi.org/10.1016/j.jocn.2016.09.017.
143. The impact of the Val158Met catechol-O-methyltransferase genotype on neural correlates of sad facial affect processing in patients with bipolar disorder and their relatives. G. Lelli-Chiesa, M. J. Kempton, J. Jogia et al. Psychological Medicine. 2011. V. 41 (4). P. 779–788. https://doi.org/10.1017/S0033291710001431.
144. The effects of gender and COMT Val158Met polymorphism on fearful facial affect recognition: a fMRI study. M. J. Kempton, M. Haldane, J. Jogia et al. Int. J. Neuropsychopharmacol. 2009. V. 12 (3). P. 371–381. https://doi.org/10.1017/S1461145708009395. Epub 2008 Sep 17.
145. The catechol-O-methyl transferase Val158Met polymorphism and experience of reward in the flow of daily life. M. Wichers, M. Aguilera, G. Kenis et al. Neuropsychopharmacol. 2008. V. 33 (13). P. 3030–3036. https://doi.org/10.1038/sj.npp.1301520.
146. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. C. W. Berridge, D. M. Devilbiss, M. E. Andrzejewski et al. Biol. Psychiatry. 2006. V. 60 (10). P. 1111–1120. https://doi.org/ 10.1016/j.biopsych.2006.04.022. Epub 2006 Jun 23.
147. Abraham A. D., Cunningham C. L., Lattal K. M. Methylphenidate enhances extinction of contextual fear. Learn Mem. 2012. V. 19 (2). P. 67–72. https://doi.org/10.1101/lm.024752.111.
148. Houlihan D. J. Psychostimulant treatment of combat-related posttraumatic stress disorder. J. Psychopharmacol. 2011. V. 25 (11). P. 1568–1572. https://doi.org/ 10.1177/0269881110385600.Epub 2010 Oct 8.
149. Randomized placebo-controlled trial of methylphenidate or galantamine for persistent emotional and cognitive symptoms associated with PTSD and/or traumatic brain injury. T. W. McAllister, R. Zafonte, S. Jain et al. Neuropsychopharmacology. 2016. V. 41 (5). P. 1191–1198. https://doi.org/
10.1038/npp.2015.282. Epub 2015 Sep 11. 150. Fear extinction rescuing effects of dopamine and L-DOPA in the ventromedial prefrontal cortex.
S. B. Sartori, T. M. V. Keil, K. K. Kummer et al. Transl. Psychiatry. 2024. V. 14 (1). P. 11. https://doi.org/10.1038/s41398-023-02708-8.
151. Haaker J., Lonsdorf T. B., Kalisch R. Effects of post-extinction l-DOPA administration on the spontaneous recovery and reinstatement of fear in a human fMRI study. Eur.
Neuropsychopharmacol. 2015. V. 25 (10). P. 1544–1555. https://doi.org/10.1016/j. euroneuro.2015.07.016. Epub 2015 Jul 21.
152. Gerlicher A. M. V., Tüscher O., Kalisch R. L-DOPA improves extinction memory retrieval after successful fear extinction. Psychopharmacology. 2019. V. 236. P. 3401–3412. https://doi.org/10.1007/s00213-019-05301-4.
153. Prescribing trends in veterans with posttraumatic stress disorder. N. C. Bernardy, B. C. Lund, B. Alexander, M. J. Friedman. J. Clin. Psychiatry. 2012. V. 73 (3). P. 297–303. https://doi.org/10.4088/JCP.11m07311.
154. Off-label use of second generation antipsychotics for post-traumatic stress disorder in the Department of Veterans Affairs: time trends and sociodemographic, comorbidity, and regional correlates. M. S. Bauer, A. Lee, M. Li et al. Pharmacoepidemiol. Drug Saf. 2014. V. 23 (1). P. 77–86. doi: 10.1002/pds.3507. Epub 2013 Aug 31.
155. Trends in medication prescribing in patients with PTSD from 2009 to 2018: a national veterans
administration study. N. Holder, A. Woods, T. C. Neylan et al. J. Clin. Psychiatry. 2021. V. 82 (3). P. 20m13522. https://doi.org/10.4088/JCP.20m13522.
156. An emulation of randomized trials of administrating antipsychotics in PTSD patients for outcomes of suicide-related events. N. R. Delapaz, W. K. Hor, M. Gilbert et al. J. Pers. Med. 2021. V. 11 (3). P. 178. https://doi.org/10.3390/jpm11030178.
157. Pharmacotherapy of 1,044 inpatients with posttraumatic stress disorder: current status and trends in German-speaking countries. M. A. Reinhard, J. Seifert, T. Greiner et al. Eur. Arch. Psychiatry. Clin. Neurosci. 2021. V. 271 (6). P. 1065–1076. https://doi.org/10.1007/s00406-020-01223-x. Epub
2020 Dec 28.
158. Richelson E., Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000. V. 68 (1). P. 29–39. https://doi.org/10.1016/s0024-3205(00)00911-5.
159. López-Muñoz F., Alamo C. Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. Front. Psychiatry. 2013. V. 4. P. 102. https://doi.org/10.3389/fpsyt.2013.00102.
160. Crapanzano C., Damiani S., Guiot C. Quetiapine in the anxiety dimension of mood disorders: a systematic review of the literature to support clinical practice. J. Clin. Psychopharmacol. 2021. V. 41 (4). P. 436–449. https://doi.org/10.1097/JCP.0000000000001420.
161. Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response. G. Nikisch, P. Baumann, T. Liu et al. Int. J. Neuropsychopharmacol. 2012. V. 15 (8). P. 1051–1061. doi: 10.1017/S1461145711001556. Epub 2011 Oct 19.
162. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. M. B. Hamner, S. E. Deitsch, P. S. Brodrick et al. J. Clin. Psychopharmacol. 2003. V. 23 (1). P. 15–20. doi: 10.1097/00004714-200302000-00003.
163. Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. E. P. Ahearn, M. Mussey, Johnson C. et al. Int. Clin. Psychopharmacol. 2006. V. 21 (1). P. 29–33. doi: 10.1097/01.yic.0000182116.49887.ae.
164. Pivac N., Kozarić-Kovacić D. Pharmacotherapy of treatment-resistant combat-related post-traumatic stress disorder with psychotic features. Croat. Med. J. 2006. V. 47 (3). P. 440–451.
165. Quetiapine for treatment of refractory symptoms of combat-related post-traumatic stress disorder. K. N. Sokolski, T. F. Denson, R. T. Lee, C. Reist. Mil. Med. 2003. V. 168 (6). P. 486–489. https://doi.org/10.1093/milmed/168.6.486.
166. Enhancing completion of cognitive processing therapy for posttraumatic stress disorder with quetiapine in veterans with mild traumatic brain injury: a case series. M. R. Baig, J. L. Wilson, J. A. Lemmer et al. Psychiatr Q. 2019. V. 90. P. 431–445. https://doi.org/10.1007/s11126-019-09638-z.
167. Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. G. M. B. Hamner , J. M. Cañive et al. Am. J. Psychiatry. 2016. V. 173 (12). P. 1205-1212. https://doi.org/10.1176/appi.ajp.2016.15070967. Epub 2016 Jul 15.
168. Quetiapine treatment for post-traumatic stress disorder: a systematic review of the literature. C. Crapanzano, S. Damiani, I. Casolaro, C. Amendola. Clin. Psychopharmacol. Neurosci. 2023. V. 21 (1). P. 49–56. doi: 10.9758/cpn.2023.21.1.49.
169. URL: https://go.drugbank.com/drugs/DB01238.
170. An open-label pilot study of aripiprazole for male and female veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants. N. A. Youssef, C. E. Marx, D. W. Bradford et al. Int. Clin. Psychopharmacol. 2012. V. 27 (4). P. 191–196. https://doi.org/10.1097/YIC.0b013e328352ef4e.
171. Lin C. C., Liu Y. P. Pharmacological implications of adjusting abnormal fear memory: towards the treatment of post-traumatic stress disorder. Pharmaceuticals (Basel). 2022. V. 15 (7). V. 788. https://doi.org/10.3390/ph15070788.
172. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator K. Maeda, H. Sugino, H. Akazawa et al. J. Pharmacol. Exp. Ther. 2014. V. 350 (3). P. 589–604. https://doi.org/10.1124/jpet.114.213793. Epub 2014 Jun 19.
173. Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole. T. Kikuchi, K. Maeda, M. Suzuki et al. Neuropsychopharmacol. Rep. 2021. V. 41 (2). P. 134–143. https://doi.org/10.1002/npr2.12180. Epub 2021 May 7.
174. Stahl S. M. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr. 2016. V. 21 (1). P. 1–6. https://doi.org/10.1017/S1092852915000954.
175. Efficacy of brexpiprazole in combination with sertraline for patients with post-traumatic stress
disorder: summary of data from phase 2 and phase 3 randomized clinical trials. L. L. Davis, B. Saloni, L. Daniel et al. JAMA Psychiatry. 2025. V. 82 (3). P. 218–227. https://doi.org/10.1001/jamapsychiatry.2024.3996.
176. Brexpiprazole in combination with sertraline and as monotherapy in posttraumatic stress disorder: a full-factorial randomized clinical trial. M. Hobart, D. Chang, N. Hefting, L. L. Davis. J. Clin. Psychiatry. 2025. V. 86 (1). P. 24m15577. https://doi.org/10.4088/JCP.24m15577.
177. Otsuka and Lundbeck present results from three clinical trials of brexpiprazole in combination with sertraline for the treatment of post-traumatic stress disorder (PTSD) in adults. Press Release May 28, 2024. URL: https://www.otsuka-us.com/news/otsuka-and-lundbeck-present-re-sults-three-clinical-trials-brexpiprazole-combination-sertraline/.
2. Effects of trauma-related audiovisual stimulation on cerebrospinal fluid norepinephrine and corticotropin-releasing hormone concentrations in post-traumatic stress disorder. T. J. Geracioti, D. G. Baker, J. W. Kasckow et al. Psychoneuroendocrinology. 2008. V. 33 (4). P. 416–424. https://doi.org/10.1016/j.psyneuen.2007.12.012. Epub 2008 Mar 4.
3. Putative dopamine agonist (KB220Z) attenuates lucid nightmares in PTSD patients: role of enhanced brain reward functional connectivity and homeostasis redeeming joy. T. McLaughlin, K. Blum, M. Oscar-Berman et al. J. Behav. Addict. 2015. V. 4 (2). P. 106–115. https://doi.org/10.1556/2006.4.2015.008.
4. O'Donnell T., Hegadoren K. M., Coupland N. C. Noradrenergic mechanisms in the pathophysiology of post-traumatic stress disorder. Neuropsychobiology. 2004. V. 50. P. 273–283. https://doi.org/10.1159/000080952.
5. Lee J. H., Lee S., Kim J. Amygdala circuits for fear memory: a key role for dopamine regulation. Neuroscientist. 2017. V. 23 (5). P. 542–553. https://doi.org/10.1177/1073858416679936. Epub 2016 Nov 21.
6. Redundant catecholamine signaling consolidates fear memory via phospholipase C. M. Ouyang, M. B. Young, M. M. Lestini et al. J. Neurosci. 2012. V. 32 (6). P. 1932–1941. https://doi.org/10.1523/JNEUROSCI.5231-11.2012.
7. Dissociation of the role of the prelimbic cortex in interval timing and resource allocation: beneficial effect of norepinephrine and dopamine reuptake inhibitor nomifensine on anxiety-inducing distraction. A. R. Matthews, O. H. He, M. Buhusi, C. V. Buhusi. Front. Integr. Neurosci. 2012. V. 6. P. 111. https://doi.org/10.3389/fnint.2012.00111. eCollection 2012.
8. Regulation of the fear network by mediators of stress: norepinephrine alters the balance between cortical and subcortical afferent excitation of the lateral amygdala. L. R. Johnson, M. Hou, E. M. Prager, J. E. LeDoux. Front. Behav. Neurosci. 2011. V. 5. P. 23. doi: 10.3389/fnbeh.2011.00023. eCollection 2011.
9. Eiden L. E. Neuropeptide-catecholamine interactions in stress. Adv. Pharmacol. 2013. V. 68. P. 399–404. https://doi.org/10.1016/B978-0-12-411512-5.00018-X.
10. Aubry A. V., Serrano P. A., Burghardtl N. S. Molecular mechanisms of stress-induced increases in fear memory consolidation within the amygdala. Front. Behav. Neurosci. 2016. V. 10. P. 191. https://doi.org/10.3389/fnbeh.2016.00191. eCollection 2016.
11. Pezze M., Feldon J. Mesolimbic dopaminergic pathways in fear conditioning. Prog. Neurobiol. 2004. V. 74 (5). P. 301–320. https://doi.org/10.1016/j.pneurobio.2004.09.004.
12. Low platelet-poor plasma concentrations of serotonin in patients with combat-related posttraumatic stress disorder. B. Spivak, Y. Vered, E. Graff et al. Biological Psychiatry. 1999. V. 4 (57). P. 840–845. https://doi.org/10.1016/S0006-3223(98)00231-5.
13. Higher cerebrospinal fluid homovanillic acid levels in depressed patients with comorbid posttraumatic stress disorder. L. Sher, M. A. Oquendo, S. Li et al. Eur. Neuropsychopharmacol. 2005. V. 15 (2). P. 203–209. https://doi.org/10.1016/j.euroneuro.2004.09.009.
14. Hendrickson R. C., Raskind M. A. Noradrenergic dysregulation in the pathophysiology of PTSD. Exp. Neurol. 2016. V. 284 (Pt B). P. 181–195. https://doi.org/10.1016/j.expneurol.2016.05.014. Epub 2016 May 2.1.
15. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride. J. C. Pruessner, F. Champagne, M. J. Meaney, A. Daghe. J. Neurosci. 2004. V. 24 (11). P. 2825–2831. https://doi.org/10.1523/JNEUROSCI.3422-03.2004.
16. Therapeutic challenges of post-traumatic stress disorder: focus on the dopaminergic system. S. A. Torrisi, G. M. Leggio, F. Drago, S. Salomone. Front. Pharmacol. 2019. V. 10. P. 404. https://doi.org/10.3389/fphar.2019.00404. eCollection 2019.
17. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. S. M. Southwick, J. D. Bremner, A. Rasmusson et al. Biological Psychiatry. 1999. V. 46 (9). P. 1192–1204.
18. CSF norepinephrine concentrations in posttraumatic stress disorder. T. D. Geracioti, D. G. Baker, N. N. Ekhator et al. Am. J. Psychiatr. 2001. V. 158. P. 1227–1230. https://doi.org/10.1176/appi.ajp.158.8.1227.
19. Enhanced noradrenergic activity in the amygdala contributes to hyperarousal in an animal model of PTSD. G. Ronzoni, A. Del Arco, F. Mora, G. Segovia. Psychoneuroendocrinology. 2016. V. 70. P. 1–9. https://doi.org/10.1016/j.psyneuen.2016.04.018. Epub 2016 Apr 25.
20. Abnormal noradrenergic function in posttraumatic stress disorder. S. M. Southwick, J. H. Krystal, C. A. Morgan et al. Arch. Gen. Psychiatr. 1993. V. 50. P. 266–274. https://doi.org/10.1001/archpsyc.1993.01820160036003.
21. Nocturnal/daytime urine noradrenergic measures and sleep in combat-related PTSD. T. A. Mellman, A. Kumar, R. Kulick-Bell et al. Biol. Psychiatr. 1995. V. 38. P. 174–179. https://doi.org/10.1016/0006-3223(94)00238-X.
22. Comparing the effect of prazosin and hydroxyzine on sleep quality in patients suffering from posttraumatic stress disorder. M. Ahmadpanah, P. Sabzeiee, S. M. Hosseini et al.
Neuropsychobiology. 2014. V. 69. P. 235–242. https://doi.org/10.1159/000362243.
23. Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US military veterans. A. Germain, R. Richardson, D. E. Moul et al. J. Psychosom. Res. 2012. V. 72. P. 89–96. https://doi.org/10.1016/j.jpsychores.2011.11.010.
24. Pitman R. K. Post-traumatic stress disorder, hormones, and memory. Biol. Psychiatry. 1989. V. 26 (3). P. 221–223.
25. Beta-adrenergic activation and memory for emotional events. L. Cahill, B. Prins, M. Weber, J. L. McGaugh. Nature. 1994. V. 371 (6499). P. 702–704. https://doi.org/10.1038/371702a0.
26. Stress reactivity links childhood trauma exposure to an admixture of depressive, anxiety, and psychosis symptoms. M. van Nierop, A. Lecei, I. Myin-Germeys et al. Psychiatr. Res. 2018. V. 260. P. 451–457. https://doi.org/10.1016/j.psychres.2017.12.012.
27. Sympathetic activity and hypothalamo-pituitary–adrenal axis activity during sleep in post- traumatic stress disorder: a study assessing polysomnography with simultaneous blood sampling. S. van Liempt, J. Arends, P. J. M. Cluitmans et al. Psychoneuroendocrinology. 2013. V. 38. P. 155–165. https://doi.org/10.1016/j.psyneuen.2012.05.015.
28. Post-traumatic stress influences the brain even in the absence of symptoms: a systematic, quantitative meta-analysis of neuroimaging studies. Stark E. A., Parsons C. E., T. J. van Hartevelt et al. Neurosci. Biobehav. Rev. 2015. V. 56. P. 207–221. https://doi.org/10.1016/j.neubiorev.2015.07.007.
29. Evidence for altered brain reactivity to norepinephrine in veterans with a history of traumatic stress. R. C. Hendrickson, M. A. Raskind, S. P. Millard et al. Neurobiol. Stress. 2018. V. 8. P. 103–111. https://doi.org/10.1016/j.ynstr.2018.03.001.
30. Amara S. G., Kuhar M. J. Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 1993. V. 16. P. 73–93. https://doi.org/10.1146/annurev.ne.16.030193.000445.
31. Pharmacology and distribution of norepinephrine transporters in the human locus coeruleus and raphe nuclei. G. A. Ordway, C. A. Stockmeier, G. W. Cason, V. Klimek. J. Neurosci. 1997. V. 17 (5). P. 1710–1719. https://doi.org/10.1523/JNEUROSCI.17-05-01710.1997.
32. Substrate binding stoichiometry and kinetics of the norepinephrine transporter. J. W. Schwartz, G. Novarino, D. W. Piston, L. J. DeFelice. J. Biol. Chem. 2005. V. 280 (19). P. 19177–19184. https://doi.org/10.1074/jbc.M412923200. Epub 2005 Mar 9.
33. Torres G. E., Gainetdinov R. R., Caron M. G. Plasma membrane monoamine transporters: structure, regulation and function. Nat. Rev. Neurosci. 2003. V. 4 (1). P. 13–25. https://doi.org/10.1038/nrn1008.
34. Hansen N. The longevity of hippocampus-dependent memory is orchestrated by the locus coeruleus-noradrenergic system. Neural. Plast. 2017. V. 2017. P. 2727602. https://doi.
org/10.1155/2017/2727602. Epub 2017 Jun 11.
35. Role of brain norepinephrine in the behavioral response to stress. D. A. Morilak, G. Barrera, D. J. Echevarria et al. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2005. V. 29 (8). P. 1214–1224. https://doi.org/10.1016/j.pnpbp.2005.08.007. Epub 2005 Oct 13.
36. Sara S. J., Bouret S. Orienting and reorienting: the locus coeruleus mediates cognition through arousal. Neuron. 2012. V. 76 (1). P. 130–1341. https://doi.org/10.1016/j.neuron.2012.09.011.
37. Jett J. D., Morilak D. A. Too much of a good thing: blocking noradrenergic facilitation in medial prefrontal cortex prevents the detrimental effects of chronic stress on cognition.
Neuropsychopharmacology. 2013. V. 38 (4). P. 585–595. https://doi.org/10.1038/npp.2012.216. Epub 2012 Nov 7.
38. Chronic stress increases the plasmalemmal distribution of the norepinephrine transporter and the coexpression of tyrosine hydroxylase in norepinephrine axons in the prefrontal cortex. L. H. Miner, H. P. Jedema, F. W. Moore et al. J. Neurosci. 2006. V. 26 (5. P. 1571–1578. https://doi.org/10.1523/JNEUROSCI.4450-05.2006.
39. Howells F. M., Stein D. J., Russell V. A. Synergistic tonic and phasic activity of the locus coeruleus norepinephrine (LC-NE) arousal system is required for optimal attentional
performance. Metab. Brain Dis. 2012. V. 27 (3). P. 267–274. https://doi.org/10.1007/s11011-012-9287-9. Epub 2012 Mar 8.
40. Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus. R. H. Pietrzak, J-D. Gallezot, Yu-Sh. Ding et al. JAMA Psychiatry. 2013. V. 70 (11). P. 1199–1205. doi:10.1001/jamapsychiatry.2013.399.
41. Norepinephrine transporter (NET) promoter and 5′-UTR polymorphisms: association analysis in panic disorder. Y. J. Lee, C. Hohoff, K. Domschke et al. Neurosci. Lett. 2005. V. 377 (1). P. 40–43. doi: 10.1016/j.neulet.2004.11.063. Epub 2004 Dec 15.
42. Association of the rs2242446 polymorphism in the norepinephrine transporter gene SLC6A2 and anxious arousal symptoms of posttraumatic stress disorder. R. H. Pietrzak, J. A. Sumner, A. E. Aiello et al. J. Clin. Psychiatry. 2015. V. 76 (4). P. e537-8. doi: 10.4088/JCP.14l09346.
43. Variable response of norepinephrine transporter to traumatic stress and relationship to hyperarousal. Ch. Nwokafor, L. I. Serovarax, A. Tanelian et al. Front. Behav. Neurosci. 2021. V. 15. P. 725091. https://doi.org/10.3389/fnbeh.2021.725091. eCollection 2021.
44. Chronic social defeat up-regulates expression of norepinephrine transporter in rat brains. P. Chen, Y. Fan, Y. Li et al. Neurochem. Int. 2012. V. 60 (1). P. 9–20. https://doi.org/10.1016/j.neuint.2011.11.003.Epub 2011 Nov 15.
45. Corticosterone administration up-regulated expression of norepinephrine transporter and dopamine β-hydroxylase in rat locus coeruleus and its terminal regions. Y. Fan, P. Chen, Y. Liet al. J. Neurochem. 2014. V. 128 (3). P. 445–458. https://doi.org/10.1111/jnc.12459. Epub 2013 Oct 10.
46. An epigenome-wide association study of posttraumatic stress disorder in US veterans implicates several new DNA methylation loci. M. W. Logue, M. W. Miller, E. J. Wolf et al. Clin. Epigenetics. 2020. V. 12 (1). P. 46. https://doi.org/10.1186/s13148-020-0820-0.
47. Association of norepinephrine transporter methylation with in vivo NET expression and hyperactivity-impulsivity symptoms in ADHD measured with PET. H. L. Sigurdardottir, G. S. Kranz, C. Rami-Mark et al. Mol. Psychiatry. 2021. V. 26 (3). P. 1009–1018. https://doi.org/10.1038/s41380-019-0461-x. Epub 2019 Aug 5.
48. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. F. Xu, R. R. Gainetdinov, W. C. Wetsel et al. Nat. Neurosci. 2000. V. 3 (5). P. 465–471. https://doi.org/10.1038/74839.
49. Spoormaker V., Montgomery P. Disturbed sleep in post-traumatic stress disorder: secondary symptom or core feature? Sleep Med. 2008. V. 12 (3). P. 169–184. https://doi.org/10.1016/j.smrv.2007.08.008.
50. Short A., Allan N. P., Schmidt N. B. Sleep disturbance as a predictor of affective functioning and symptom severity among individuals with PTSD: an ecological momentary assessment study. Behav. Res. Ther. 2017. V. 97. P. 146–153. https://doi.org/10.1016/j.brat.2017.07.014. Epub 2017 Jul 27.
51. National institute for health and care excellence. Post-traumatic stress disorder (NICE Quality Standard NG116) 2018 [Internet] c [cited 2019 Sep 9]. URL: https://www.nice.org.uk.guidance/ng116/evidenc.
52. Australian guidelines for the prevention and treatment of acute stress disorder, posttraumatic stress disorder, and complex posttraumatic stress disorder. Phoenix Australia centre for posttraumatic mental health. National health and medical research council. Canberra, Australia, 2020.
53. Veterans health administration, department of defense. VA/DoD clinical practice guideline for the management of post-traumatic stress. Washington : veterans health administration, Department of Defense, 2017.
54. Clinical practice guideline for the treatment of posttraumatic stress disorder (PTSD) in adults. American psychological association, Guideline development panel for the treatment of PTSD in adults. 2017. URL: https://www.apa.org/ptsd-guideline.
55. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo controlled study. M. A. Raskind, E. R. Peskind, E. D. Kanter et al. Am. J. Psychiatry. 2003. V. 160 (2). V. 371–373. https://doi.org/10.1176/appi.ajp.160.2.371.
56. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. M. A. Raskind, E. R. Peskind, D. J. Hoff et al. Biol. Psychiatry. 2007. V. 61 (8). P. 928–934. https://doi.org/10.1016/j.biopsych.2006.06.032.
57. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. M. A. Raskind, K. Peterson, T. Williams et al. Am. J. Psychiatry. 2013. V. 170 (9). P. 1003–1010. https://doi.org/10.1176/appi.ajp.2013.12081133.
58. Naltrexone and prazosin combination for posttraumatic stress disorder and alcohol use disorder. H. Qazi, H. Wijegunaratne, R. Savajiyani, M. M. Koola. Prim. Care Companion CNS Disord. 2014. V. 16 (4). P. 14l01638. https://doi.org/10.4088/PCC.14l01638.
59. Fludrocortisone in posttraumatic stress disorder: effective for symptoms and prazosin-induced hypotension. M. Vaishnav, V. Patel, S. P. Varghese et al. Prim. Care Companion CNS Disord. 2014. V. 16 (6). P. 14l01676. https://doi.org/10.4088/PCC.14l01676.
60. Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety. M. G. Byers, K. M. Allison, C. S. Wendel, J. K. Lee. J. Clin. Psychopharmacol. 2010. V. 30 (3). P. 225–229. https://doi.org/10.1097/JCP.0b013e3181dac52f.
61. Trial of prazosin for post-traumatic stress disorder in military veterans. M. A. Raskind, E. R. Peskind, B. Chow et al. New England Journal of Medicine. 2018. V. 378 (6). P. 507–517.
62. The effects of prazosin on sleep disturbances in post-traumatic stress disorder: a systematic review and meta-analysis. Y. Zhang, R. Ren, L. D. Sanford et al. Sleep Med. 2020. V. 67. P. 225–231. https://doi.org/10.1016/j.sleep.2019.06.010. Epub 2019 Jun 22.
63. Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis. C. Reist, E. Streja, C. C. Tang et al. CNS Spectrums. 2021. V. 26 (4). P. 338–344.
64. Efficacy of prazosin in posttraumatic stress disorder: a systematic review and meta-analysis. B. Singh, A. J. Hughes, G. Mehta et al. Prim. Care Companion CNS Disord. 2016. V. 18 (6).
65. Sethi R., Vasudeva S. Doxazosin for treatment of nightmares: does it really work? A case report. Prim. Care Companion CNS Disord. 2012. V. 14 (5). P. 12l01356. https://doi.org/10.4088/PCC.12l01356.
66. Doxazosin treatment for posttraumatic stress disorder. J. De Jong, P. Wauben, I. Huijbrects et al. J. Clin. Psychopharmacol. 2010. V. 30 (1). P. 84–85. https://doi.org/10.1097/JCP.0b013e3181c827ae.
67. Smith Ch., Koola M. M. Evidence for using doxazosin in the treatment of posttraumatic stress disorder. Psychiatr. Ann. 2016. V. 46 (9). P. 553–555. https://doi.org/10.3928/00485713-20160728-01.
68. Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial. C. Rodgman, C. D. Verrico, M. Holst et al. J. Clin. Psychiatry. 2016. V. 77 (5). P. e561–e565. https://doi.org/10.4088/JCP.14m09681.
69. Doxazosin, an alpha-1-adrenergic-receptor antagonist, for nightmares in patients with posttraumatic stress disorder and/or borderline personality disorder: a chart review. S. Roepke, H. Danker-Hopfe, D. Repantis et al. Pharmacopsychiatry. 2017. V. 50 (1). P. 26–31. https://doi.org/10.1055/s-0042-107794. Epub 2016 Jun 8.
70. Khan D., Richardson C., Forsberg Martin. Doxazosin immediate release as a novel treatment for nightmares in posttraumatic stress disorder. Case Rep. Psychiatry. 2024. V. 2024. P. 6452923. https://doi.org/10.1155/crps/6452923. eCollection 2024.
71. An open-label study of doxazosin extended-release for PTSD: findings and recommendations for future research on doxazosin. A. Richards S., Inslicht, L. M. Ruoff еt al. Focus (Am. Psychiatr. Publ.). 2018. V. 16 (1). P. 67–73. https://doi.org/10.1176/appi.focus.20170031. Epub 2018 Jan 24.
72. Khan Z. P., Ferguson C. N., Jones R. M. Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia. 1999. V. 54 (2). P. 146–165. https://doi.
org/10.1046/j.1365-2044.1999.00659.x.
73. Marchi M., Grenzi P., Boks M. Clonidine for post-traumatic stress disorder: a systematic review of the current evidence. Eur. J. Psychotraumatol. 2024. V. 15 (1). P. 2366049. https://doi.org/10.1080/20008066.2024.2366049. Epub 2024 Jun 28.
74. Inhibition of noradrenaline release by clonidine in the ventral bed nucleus of the stria terminalis attenuates pain-induced aversion in rats. S. Deyama, S. Ide, N. Kondoh et al. Neuropharmacology. 2011. V. 61 (1–2). P. 156–160.
75. Lebow M. A., Chen A. Overshadowed by the amygdala: the bed nucleus of the stria terminalis emerges as key to psychiatric disorders. Molecular Psychiatry. 2016. V. 21 (4). P. 450–463. https://doi.org/10.1038/mp.2016.1.
76. Katic F., Lavery H., Lowe R. D. The central action of clonidine and its antagonism. British Journal of Pharmacology. 1972. V. 44 (4). P. 779–787.
77. Clonidine effects on all-night human sleep: opposite action of low- and medium-dose clonidine on human NREM-REM sleep proportion. S. Miyazaki, S. Uchida, J. Mukai, K. Nishihara. Psychiatry and Clinical Neurosciences. V. 58 (2). P. 138–144.
78. Taking advantage of fear generalization-associated destabilization to attenuate the underlying memory via reconsolidation intervention. F. N. Marin, J. M. Franzen, F. Troyner et al. Neuropharmacology. 2020. V. 181. P. 108338. https://doi.org/10.1016/j.neuropharm.2020.108338. Epub 2020 Sep 28.
79. Activation of a novel α2AAR-spinophilin-cofilin axis determines the effect of α2 adrenergic drugs on fear memory reconsolidation. S. Saggu, Y. Chen, C. Cottingham et al. Molecular Psychiatry. 2023. V. 28 (2). P. 588–600. https://doi.org/10.1038/s41380-022-01851-w.
80. Schulz B., Fendt M., Schnitzler H-U. Clonidine injections into the lateral nucleus of the amygdala block acquisition and expression of fear-potentiated startle. European Journal of Neuroscience. 2002. V. 15 (1). P. 151–157.
81. Low-dose clonidine in veterans with posttraumatic stress disorder. G. A. Burek, M. R. Waite, K. Heslin et al. J. Psychiatr. Res. 2021. V. 137. P. 480–485. https://doi.org/10.1016/j.
jpsychires.2021.03.008. Epub 2021 Mar 16.
82. Treatment of post-traumatic stress disorder nightmares at a veterans affairs medical center. M. B. Detweiler, B. Pagadala, J. Candelario et al. J. Clin. Med. 2016. V. 5 (12). P. 117. https://doi.org/10.3390/jcm5120117.
83. Wendell K. R., Maxwell M. L. Evaluation of clonidine and prazosin for the treatment of nighttime posttraumatic stress disorder symptoms. Fed. Pract. 2015. V. 32 (11). P. 8–14.
84. Eye movement desensitization and reprocessing for mental health problems: a systematic review and meta-analysis. P. Cuijpers, S. C. van Veen, M. Sijbrandij et al. Cogn. Behav. Ther. 2020. V. 49 (3). P. 165–180. https://doi.org/10.1080/16506073.2019.1703801. Epub 2020 Feb 11.
85. Contribution of norepinephrine to emotional memory consolidation during sleep. S. Groch, I. Wilhelm, S. Diekelmann et al. Psychoneuroendocrinology. 2011. V. 36 (9). P. 1342–1350. https://doi.org/10.1016/j.psyneuen.2011.03.006. Epub 2011 Apr 13.
86. Srinivasan A. V. Propranolol: a 50-year historical perspective. Ann. Indian Acad. Neurol. 2019. V. 22 (1). P. 21–26. https://doi.org/10.4103/aian.AIAN_201_18.
87. Giustino T. F., Fitzgerald P. J., Maren S. Revisiting propranolol and PTSD: memory erasure or extinction enhancement? Neurobiol. Learn Mem. 2016. V. 130. P. 26–33. https://doi.org/10.1016/j.nlm.2016.01.009. Epub 2016 Jan 22.
88. Young C., Butcher R. Propranolol for post-traumatic stress disorder: a review of clinical effectiveness. CADTH rapid response report: summary with critical appraisal. Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2020. https://www.ncbi.nlm.nih.gov/books/NBK562942/#rc1254.rl.r1.
89. Propranolol’s impact on cognitive performance in post-traumatic stress disorder. M. Mahabir, A. R. Ashbaugh, D. Saumier, J. Tremblay. J. Affect. Disord. 2016. V. 192. P. 98–103. https://doi.org/10.1016/j.jad.2015.11.051. Epub 2015 Dec 8.
90. Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury. D. C. Orrey, O. I. Halawa, A. V. Bortsov et al. Clin. J. Pain. 2015. V. (1). P. 21–29. https://doi.org/10.1097/AJP.0000000000000086.
91. Altered forebrain neurotransmitter responses to immobilization stress following 3,4-methylenedioxymethamphetamine. L. Matuszewich, M. E. Filon, D. A. Finn, B. K. Yamamoto. Neuroscience. 2002. V. 110 (1). P. 41–48. https://doi.org/10.1016/s0306-4522(01)00539-5.
92. Anxiolytic-like actions of reboxetine, venlafaxine and endurance swimming in stressed male rats. S. Lapmanee, N. Charoenphandhu, N. Krishnamra, J. Charoenphandhu. Behav. Brain Res. 2012. V. 231 (1). P. 20–28. https://doi.org/10.1016/j.bbr.2012.02.037. Epub 2012 Mar 1.
93. Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine. Z. Zhao, A. M. Baros, H-T. Zhang et al. Neuropsychopharmacology. 2008. V. 33 (13). P. 3190–3200. https://doi.org/10.1038/npp.2008.45.
94. Ipser J. C., Stein D. J. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int. J. Neuropsychopharmacol. 2012. V. 15 (6). P. 825–840. https://doi.org/10.1017/S1461145711001209. Epub 2011 Jul 29.
95. Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. I. L. Petrakis, E. Ralevski, N. Desai et al.
Neuropsychopharmacology. 2012. V. 37 (4). P. 996–1004. https://doi.org/10.1038/npp.2011.283.Epub 2011 Nov 16.
96. Therapeutic challenges of post-traumatic stress disorder: focus on the dopaminergic system. S. A. Torrisi, G. M. Leggio, F. Drago, S. Salomone. Front. Pharmacol. 2019. V. 10. P. 404. https://doi.org/10.3389/fphar.2019.00404. eCollection 2019.
97. Lee J. C., Wang L. P., Tsien J. Z. Dopamine rebound-excitation theory: putting brakes on PTSD. Front. Psychiatry. 2016. V. 7. P. 163. https://doi.org/10.3389/fpsyt.2016.00163. eCollection 2016.
98. Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti-reward systems. M. S. Gold, K. Blum, M. Febo et al. Front. Biosci. (Schol Ed). 2018. V. 10 (2). P. 309–325. https://doi.org/10.2741/s518.
99. The medial prefrontal cortex determines the accumbens dopamine response to stress through the opposing influences of norepinephrine and dopamine. T. Pascucci, R. Ventura, E. C. Latagliata et al. Cereb. Cortex. 2007. V. 17 (12). P. 2796–2804. https://doi.org/10.1093/cercor/bhm008. Epub 2007 Feb 24.
100. Cabib S., Puglisi-Allegra S. The mesoaccumbens dopamine in coping with stress. Neurosci Biobehav Rev. 2012. V. 36 (1). P. 79–89. https://doi.org/10.1016/j.neubiorev.2011.04.012. Epub 2011 May 4.
101. Enhancing depression mechanisms in midbrain dopamine neurons achieves homeostatic resilience. A. K. Friedman, J. J. Walsh, B. Juarezet al. Science. 2014. V. 344 (6181). P. 313–319. https://doi.org/10.1126/science.1249240.
102. Torres G. E., Gainetdinov R. R., Caron M. G. Plasma membrane monoamine transporters: structure, regulation and function. Nature Reviews Neuroscience. 2003. V. 4 (1). P. 13–25. https://doi.org/10.1038/nrn1008.
103. Ramamoorthy S., Shippenberg T., Lankupalle J. Regulation of monoamine transporters: role of transporter phosphorylation. Pharmacol. Ther. 2011. V. 129 (2). P. 220–238. https://doi.org/10.1016/j.pharmthera.2010.09.009. Epub 2010 Oct 15.
104. Hillarp N. A., Fuxe K., Dahlstrom A. Demonstration and mapping of central neurons containing dopamine, noradrenaline, and 5-hydroxytryptamine and their reactions to psychopharmaca. Pharmacol. Rev. 1966. V. 18 (1). P. 727–741.
105. Dorsal raphe dopamine neurons represent the experience of social isolation. G. A. Matthews, E. H. Nieh, C. M. Vander Weele et al. Cell. 2016. V. 164 (4). P. 617–631. https://doi.org/10.1016/j.cell.2015.12.040.
106. Dorsal raphe dopamine neurons modulate arousal and promote wakefulness by salient stimuli. J. R. Cho, J. B. Treweek, J. E. Robinson et al. Neuron. 2017. V. 94 (6). P. 1205–1219.e8. https://doi.org/10.1016/j.neuron.2017.05.020. Epub 2017 Jun 8.
107. Dorsal tegmental dopamine neurons gate associative learning of fear. F. Groessl, T. Munsch, S. Meis et al. Nat. Neurosci. 2018. V. 21 (7). P. 952–962. https://doi.org/10.1038/s41593-018-0174-5. Epub 2018 Jun 27.
108. Brewin C. R. Re-experiencing traumatic events in PTSD: new avenues in research on intrusive
memories and flashbacks. Eur. J. Psychotraumatol. 2015. V. 6. P. 27180. https://doi.org/10.3402/ejpt.v6.27180. eCollection 2015.
109. Emotion modulation in PTSD: clinical and neurobiological evidence for a dissociative subtype.
R. A. Lanius, E. Vermetten, R. J. Loewenstein et al. Am. J. Psychiatry. 2010. V. 167 (6). P. 640–647. https://doi.org/10.1176/appi.ajp.2009.09081168. Epub 2010 Apr 1.
110. Hikind N., Maroun M. Microinfusion of the D1 receptor antagonist, SCH23390 into the IL but not the BLA impairs consolidation of extinction of auditory fear conditioning. Neurobiol. Learn Mem. 2008. V. 90 (1). P. 217–222. https://doi.org/10.1016/j.nlm.2008.03.003. Epub 2008 Apr 28.
111. Mueller D., Bravo-Rivera C., Quirk G. J. Infralimbic D2 receptors are necessary for fear extinction and extinction-related tone responses. Biol. Psychiatry. 2010. V. 68 (11). P. 1055–1060. https://doi.org/10.1016/j.biopsych.2010.08.014.
112. Single dose of L-dopa makes extinction memories context-independent and prevents the return of fear. J. Haaker, S. Gaburro, A. Sah et al. Proc. Natl. Acad. Sci. USA. 2013. V. 110 (26). P. E2428–E2436. https://doi.org/10.1073/pnas.1303061110. Epub 2013 Jun 10.
113. Gerlicher A. M. V., Tuscher O., Kalisch R. Dopamine-dependent prefrontal reactivations explain long-term benefit of fear extinction. Nat. Commun. 2018. V. 9 (1). P. 4294. https://doi.org/10.1038/s41467-018-06785-y.
114. Stein M. B., Paulus M. P. Imbalance of approach and avoidance: the yin and yang of anxiety disorders. Biol. Psychiatry. 2009. V. 66 (12). P. 1072–1074. https://doi.org/10.1016/j.
biopsych.2009.09.023.
115. Contreras-Vidal J. L., Schultz W. A predictive reinforcement model of dopamine neurons for learning approach behavior. J. Comput. Neurosci. 1999. V. 6 (3). V. 191–214. https://doi.org/10.1023/a:1008862904946.
116. Schultz W. Behavioral dopamine signals. Trends Neurosci. 2007. V. 30 (5). P. 203–210. https://doi. org/10.1016/j.tins.2007.03.007. Epub 2007 Apr 2.
117. Dopamine enhances signal-to-noise ratio in cortical-brainstem encoding of aversive stimuli. C. M. Vander Weele, C. A. Siciliano, G. A. Matthews et al. Nature. 2018. V. 563 (7731). P. 397–401. https://doi.org/10.1038/s41586-018-0682-1. Epub 2018 Nov 7.
118. Dopamine neurons projecting to the posterior striatum reinforce avoidance of threatening stimuli. W. Menegas, K. Akiti, R. Amo et al. Nat. Neurosci. 2018. V. 21 (10). P. 1421–1430. https://doi.org/10.1038/s41593-018-0222-1. Epub 2018 Sep 3.
119. Striatopallidal neurons control avoidance behavior in exploratory tasks. K. H. LeBlanc, T. D. London, I. Szczot et al. Mol. Psychiatry. 2020. V. 25 (2). P. 491–505. https://doi.org/10.1038/s41380-018-0051-3. Epub 2018 Apr 25.
120. How the brain translates money into force: a neuroimaging study of subliminal motivation. M. Pessiglione, L. Schmidt, B. Draganski et al. Science. 2007. V. 316 (5826). P. 904–906. https://doi.org/10.1126/science.1140459. Epub 2007 Apr 12.
121. Hayes J. P., Vanelzakker M. B., Shin L. M. Emotion and cognition interactions in PTSD: a review of neurocognitive and neuroimaging studies. Front. Integr. Neurosci. 2012. V. 6. P. 89. https://doi.org/10.3389/fnint.2012.00089. eCollection 2012.
122. Anhedonia, reduced cocaine reward, and dopamine dysfunction in a rat model of posttraumatic stress disorder. N. M. Enman, K. Arthur, S. J. Ward et al. Biol. Psychiatry. 2015. V. 78 (12). P. 871–879. https://doi.org/10.1016/j.biopsych.2015.04.024. Epub 2015 May 6.
123. Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse. J. D. Bremner, S. M. Southwick, A. Darnell, D. S. Charney. Am. J. Psychiatry. 1996. V. 153 (3). P. 369–375. https://doi.org/10.1176/ajp.153.3.369.
124. Schell T. L., Marshall G. N., Jaycox L. H. All symptoms are not created equal: the prominent role of hyperarousal in the natural course of posttraumatic psychological distress. J. Abnorm. Psychol. 2004. V. 113 (2). P.189–197. https://doi.org/10.1037/0021-843X.113.2.189.
125. Weston C. S. Posttraumatic stress disorder: a theoretical model of the hyperarousal subtype. Front. Psychiatry. 2014. V. 5. P. 37. https://doi.org/10.3389/fpsyt.2014.00037. eCollection 2014.
126. Dalley J. W., Roiser J. P. Dopamine, serotonin and impulsivity. Neuroscience. 2012. V. 215. P. 42–58. https://doi.org/10.1016/j.neuroscience.2012.03.065. Epub 2012 Apr 25.
127. Cocaine modulation of frontostriatal expression of Zif268, D2, and 5-HT2c receptors in high and low impulsive rats. M. Besson, Y. Pelloux, R. Dilleen et al. Neuropsychopharmacology. 2013. V. 38 (10). P. 1963–1973. https://doi.org/10.1038/npp.2013.95. Epub 2013 May 1.
128. Brain circuit dysfunction in post-traumatic stress disorder: from mouse to man. R. J. Fenster, L. A. M. Lebois, K. J. Ressler, J. Suh. Nat. Rev. Neurosci. 2018. P. 19 (9). P. 535–551. https://doi.org/10.1038/s41583-018-0039-7.
129. Monti J. M., Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med. Rev. 2007. V. 11 (2). P. 113–133. https://doi.org/10.1016/j.smrv.2006.08.003. Epub 2007 Feb 1.
130. Prominent burst firing of dopaminergic neurons in the ventral tegmental area during paradoxical sleep. L. Dahan, B. Astier, N. Vautrelle et al. Neuropsychopharmacology. 2007. V. 32 (6). P. 1232– 1241. https://doi.org/10.1038/sj.npp.1301251.
131. Optogenetic activation of dopamine neurons in the ventral tegmental area induces reanimation from general anesthesia. N. E. Taylor, C. J. Van Dort, J. D. Kenny et al. Proc. Natl. Acad. Sci. USA. 2016. V. 113 (45). P. 12826–12831. https://doi.org/10.1073/pnas.1614340113. Epub 2016 Oct 24.
132. VTA dopaminergic neurons regulate ethologically relevant sleep-wake behaviors. A. Eban- Rothschild, G. Rothschild, W. J. Giardino et al. Nat. Neurosci. 2016. V. 19 (10). P.1356–1366. https://doi.org/10.1038/nn.4377. Epub 2016 Sep 5.
133. Current drug treatments targeting dopamine D3 receptor. G. M. Leggio, C. Bucolo, C. B. Platania et al. Pharmacol. Ther. 2016. V. 165. P. 164–177. https://doi.org/10.1016/j.pharmthera.2016.06.007.Epub 2016 Jun 22.
134. The D2 dopamine receptor (DRD2) gene is associated with co-morbid depression, anxiety and social dysfunction in untreated veterans with post-traumatic stress disorder. B. R. Lawford, R. Young, E. P. Noble et al. European Psychiatry. 2006. V. 21 (3). P. 180–185. https://doi.org/
135. Loiseau F., Millan M. J. Blockade of dopamine D3 receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D1 receptor agonists, but not of D2 antagonists. Eur. Neuropsychopharmacol. 2009. V. 19 (1). P. 23–33. https://doi.org/10.1016/j.
euroneuro.2008.07.012. Epub 2008 Sep 14.
136. The dopamine D3 receptor gene and posttraumatic stress disorder. E. J. Wolf, K. S. Mitchell, M. W. Logue et al. J. Trauma Stress. 2014. V. 27 (4). P. 379–87. https://doi.org/10.1002/jts.21937.
137. Role of dopamine D3 receptor in alleviating behavioural deficits in animal models of post-traumatic stress disorder. D. Song , Y. Ge, Z. Chen et al. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2018. V. 84 (Pt A). P. 190–200. https://doi.org/10.1016/j.pnpbp.2018.03.001. Epub 2018 Mar 3.
138. Dopamine D3 receptor in the nucleus accumbens alleviates neuroinflammation in a mouse modelof depressive-like behavior. J. Wang, S. Lai, R. Wang et al. Brain Behav. Immun. V. 101. P. 165–179. https://doi.org/10.1016/j.bbi.2021.12.019. Epub 2021 Dec 28.
139. COMT as a drug target for cognitive functions and dysfunctions. D. Scheggia, S. Sannino, M. L. Scattoni, F. Papaleo. CNS Neurol. Disord. Drug Targets. 2012. V. 11 (3). P. 209–221. https://doi.org/10.2174/187152712800672481.
140. Diaz-Asper C. M., Weinberger D. R., Goldberg T. E. Catechol-O-methyltransferase polymorphisms and some implications for cognitive therapeutics. NeuroRx. 2006. V. 3 (1). P. 97–105. https://doi.org/10.1016/j.nurx.2005.12.010.
141. Schacht J. P. COMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review. The Pharmacogenomics Journal. 2016. 16 (5). P. 430–438. https://doi.org/10.1038/tpj.2016.43.
142. COMT Val158Met polymorphism is associated with post-traumatic stress disorder and functional outcome following mild traumatic brain injury. E. A. Winkler, J. Yue, A. R. Ferguson et al. J. Clin. Neurosci. 2016. V. 35. P. 109–116. https://doi.org/10.1016/j.jocn.2016.09.017.
143. The impact of the Val158Met catechol-O-methyltransferase genotype on neural correlates of sad facial affect processing in patients with bipolar disorder and their relatives. G. Lelli-Chiesa, M. J. Kempton, J. Jogia et al. Psychological Medicine. 2011. V. 41 (4). P. 779–788. https://doi.org/10.1017/S0033291710001431.
144. The effects of gender and COMT Val158Met polymorphism on fearful facial affect recognition: a fMRI study. M. J. Kempton, M. Haldane, J. Jogia et al. Int. J. Neuropsychopharmacol. 2009. V. 12 (3). P. 371–381. https://doi.org/10.1017/S1461145708009395. Epub 2008 Sep 17.
145. The catechol-O-methyl transferase Val158Met polymorphism and experience of reward in the flow of daily life. M. Wichers, M. Aguilera, G. Kenis et al. Neuropsychopharmacol. 2008. V. 33 (13). P. 3030–3036. https://doi.org/10.1038/sj.npp.1301520.
146. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. C. W. Berridge, D. M. Devilbiss, M. E. Andrzejewski et al. Biol. Psychiatry. 2006. V. 60 (10). P. 1111–1120. https://doi.org/ 10.1016/j.biopsych.2006.04.022. Epub 2006 Jun 23.
147. Abraham A. D., Cunningham C. L., Lattal K. M. Methylphenidate enhances extinction of contextual fear. Learn Mem. 2012. V. 19 (2). P. 67–72. https://doi.org/10.1101/lm.024752.111.
148. Houlihan D. J. Psychostimulant treatment of combat-related posttraumatic stress disorder. J. Psychopharmacol. 2011. V. 25 (11). P. 1568–1572. https://doi.org/ 10.1177/0269881110385600.Epub 2010 Oct 8.
149. Randomized placebo-controlled trial of methylphenidate or galantamine for persistent emotional and cognitive symptoms associated with PTSD and/or traumatic brain injury. T. W. McAllister, R. Zafonte, S. Jain et al. Neuropsychopharmacology. 2016. V. 41 (5). P. 1191–1198. https://doi.org/
10.1038/npp.2015.282. Epub 2015 Sep 11. 150. Fear extinction rescuing effects of dopamine and L-DOPA in the ventromedial prefrontal cortex.
S. B. Sartori, T. M. V. Keil, K. K. Kummer et al. Transl. Psychiatry. 2024. V. 14 (1). P. 11. https://doi.org/10.1038/s41398-023-02708-8.
151. Haaker J., Lonsdorf T. B., Kalisch R. Effects of post-extinction l-DOPA administration on the spontaneous recovery and reinstatement of fear in a human fMRI study. Eur.
Neuropsychopharmacol. 2015. V. 25 (10). P. 1544–1555. https://doi.org/10.1016/j. euroneuro.2015.07.016. Epub 2015 Jul 21.
152. Gerlicher A. M. V., Tüscher O., Kalisch R. L-DOPA improves extinction memory retrieval after successful fear extinction. Psychopharmacology. 2019. V. 236. P. 3401–3412. https://doi.org/10.1007/s00213-019-05301-4.
153. Prescribing trends in veterans with posttraumatic stress disorder. N. C. Bernardy, B. C. Lund, B. Alexander, M. J. Friedman. J. Clin. Psychiatry. 2012. V. 73 (3). P. 297–303. https://doi.org/10.4088/JCP.11m07311.
154. Off-label use of second generation antipsychotics for post-traumatic stress disorder in the Department of Veterans Affairs: time trends and sociodemographic, comorbidity, and regional correlates. M. S. Bauer, A. Lee, M. Li et al. Pharmacoepidemiol. Drug Saf. 2014. V. 23 (1). P. 77–86. doi: 10.1002/pds.3507. Epub 2013 Aug 31.
155. Trends in medication prescribing in patients with PTSD from 2009 to 2018: a national veterans
administration study. N. Holder, A. Woods, T. C. Neylan et al. J. Clin. Psychiatry. 2021. V. 82 (3). P. 20m13522. https://doi.org/10.4088/JCP.20m13522.
156. An emulation of randomized trials of administrating antipsychotics in PTSD patients for outcomes of suicide-related events. N. R. Delapaz, W. K. Hor, M. Gilbert et al. J. Pers. Med. 2021. V. 11 (3). P. 178. https://doi.org/10.3390/jpm11030178.
157. Pharmacotherapy of 1,044 inpatients with posttraumatic stress disorder: current status and trends in German-speaking countries. M. A. Reinhard, J. Seifert, T. Greiner et al. Eur. Arch. Psychiatry. Clin. Neurosci. 2021. V. 271 (6). P. 1065–1076. https://doi.org/10.1007/s00406-020-01223-x. Epub
2020 Dec 28.
158. Richelson E., Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000. V. 68 (1). P. 29–39. https://doi.org/10.1016/s0024-3205(00)00911-5.
159. López-Muñoz F., Alamo C. Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. Front. Psychiatry. 2013. V. 4. P. 102. https://doi.org/10.3389/fpsyt.2013.00102.
160. Crapanzano C., Damiani S., Guiot C. Quetiapine in the anxiety dimension of mood disorders: a systematic review of the literature to support clinical practice. J. Clin. Psychopharmacol. 2021. V. 41 (4). P. 436–449. https://doi.org/10.1097/JCP.0000000000001420.
161. Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response. G. Nikisch, P. Baumann, T. Liu et al. Int. J. Neuropsychopharmacol. 2012. V. 15 (8). P. 1051–1061. doi: 10.1017/S1461145711001556. Epub 2011 Oct 19.
162. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. M. B. Hamner, S. E. Deitsch, P. S. Brodrick et al. J. Clin. Psychopharmacol. 2003. V. 23 (1). P. 15–20. doi: 10.1097/00004714-200302000-00003.
163. Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. E. P. Ahearn, M. Mussey, Johnson C. et al. Int. Clin. Psychopharmacol. 2006. V. 21 (1). P. 29–33. doi: 10.1097/01.yic.0000182116.49887.ae.
164. Pivac N., Kozarić-Kovacić D. Pharmacotherapy of treatment-resistant combat-related post-traumatic stress disorder with psychotic features. Croat. Med. J. 2006. V. 47 (3). P. 440–451.
165. Quetiapine for treatment of refractory symptoms of combat-related post-traumatic stress disorder. K. N. Sokolski, T. F. Denson, R. T. Lee, C. Reist. Mil. Med. 2003. V. 168 (6). P. 486–489. https://doi.org/10.1093/milmed/168.6.486.
166. Enhancing completion of cognitive processing therapy for posttraumatic stress disorder with quetiapine in veterans with mild traumatic brain injury: a case series. M. R. Baig, J. L. Wilson, J. A. Lemmer et al. Psychiatr Q. 2019. V. 90. P. 431–445. https://doi.org/10.1007/s11126-019-09638-z.
167. Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. G. M. B. Hamner , J. M. Cañive et al. Am. J. Psychiatry. 2016. V. 173 (12). P. 1205-1212. https://doi.org/10.1176/appi.ajp.2016.15070967. Epub 2016 Jul 15.
168. Quetiapine treatment for post-traumatic stress disorder: a systematic review of the literature. C. Crapanzano, S. Damiani, I. Casolaro, C. Amendola. Clin. Psychopharmacol. Neurosci. 2023. V. 21 (1). P. 49–56. doi: 10.9758/cpn.2023.21.1.49.
169. URL: https://go.drugbank.com/drugs/DB01238.
170. An open-label pilot study of aripiprazole for male and female veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants. N. A. Youssef, C. E. Marx, D. W. Bradford et al. Int. Clin. Psychopharmacol. 2012. V. 27 (4). P. 191–196. https://doi.org/10.1097/YIC.0b013e328352ef4e.
171. Lin C. C., Liu Y. P. Pharmacological implications of adjusting abnormal fear memory: towards the treatment of post-traumatic stress disorder. Pharmaceuticals (Basel). 2022. V. 15 (7). V. 788. https://doi.org/10.3390/ph15070788.
172. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator K. Maeda, H. Sugino, H. Akazawa et al. J. Pharmacol. Exp. Ther. 2014. V. 350 (3). P. 589–604. https://doi.org/10.1124/jpet.114.213793. Epub 2014 Jun 19.
173. Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole. T. Kikuchi, K. Maeda, M. Suzuki et al. Neuropsychopharmacol. Rep. 2021. V. 41 (2). P. 134–143. https://doi.org/10.1002/npr2.12180. Epub 2021 May 7.
174. Stahl S. M. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr. 2016. V. 21 (1). P. 1–6. https://doi.org/10.1017/S1092852915000954.
175. Efficacy of brexpiprazole in combination with sertraline for patients with post-traumatic stress
disorder: summary of data from phase 2 and phase 3 randomized clinical trials. L. L. Davis, B. Saloni, L. Daniel et al. JAMA Psychiatry. 2025. V. 82 (3). P. 218–227. https://doi.org/10.1001/jamapsychiatry.2024.3996.
176. Brexpiprazole in combination with sertraline and as monotherapy in posttraumatic stress disorder: a full-factorial randomized clinical trial. M. Hobart, D. Chang, N. Hefting, L. L. Davis. J. Clin. Psychiatry. 2025. V. 86 (1). P. 24m15577. https://doi.org/10.4088/JCP.24m15577.
177. Otsuka and Lundbeck present results from three clinical trials of brexpiprazole in combination with sertraline for the treatment of post-traumatic stress disorder (PTSD) in adults. Press Release May 28, 2024. URL: https://www.otsuka-us.com/news/otsuka-and-lundbeck-present-re-sults-three-clinical-trials-brexpiprazole-combination-sertraline/.